Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Sell
13
MDXH Quote, Financials, Valuation and Earnings
Last price:
$1.4200
Seasonality move
:
33980%
Day range:
$1.3600 - $1.4450
52-week range:
$1.3500 - $3.5000
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.59x
P/B ratio:
4.70x
Volume:
99.6K
Avg. volume:
89.5K
1-year change:
-43.37%
Market cap:
$69.8M
Revenue:
$90M
EPS (TTM):
-$1.27
Analysts' Opinion
-
Consensus RatingMDxHealth SA has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.0400, MDxHealth SA has an estimated upside of 328.37% from its current price of $1.4100.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.2000 representing 100% downside risk from its current price of $1.4100.
Fair Value
-
According to the consensus of 5 analysts, MDxHealth SA has 328.37% upside to fair value with a price target of $6.0400 per share.
MDXH vs. S&P 500
-
Over the past 5 trading days, MDxHealth SA has underperformed the S&P 500 by -12.59% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
MDxHealth SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MDxHealth SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter MDxHealth SA reported revenues of $24.7M.
Earnings Growth
-
MDxHealth SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MDxHealth SA reported earnings per share of -$0.14.
Enterprise value:
74.3M
EV / Invested capital:
--
Price / LTM sales:
0.59x
EV / EBIT:
--
EV / Revenue:
0.82x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.59x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$55.1M
Return On Assets:
-26.5%
Net Income Margin (TTM):
-42.28%
Return On Equity:
-395.93%
Return On Invested Capital:
-68.89%
Operating Margin:
-18.63%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $37.1M | $70.2M | $90M | $19.4M | $24.7M | |
| Gross Profit | $19.2M | $43.9M | $55.1M | $12.7M | $15.5M | |
| Operating Income | -$38.4M | -$26.7M | -$24M | -$5.7M | -$3.9M | |
| EBITDA | -$36.7M | -$33.6M | -$24.8M | -$15.3M | -$8M | |
| Diluted EPS | -$2.78 | -$1.67 | -$1.27 | -$0.39 | -$0.14 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $23.1M | $66.6M | $29.1M | $38.2M | $66.9M | |
| Total Assets | $31.9M | $75.1M | $119.1M | $129.1M | $157.3M | |
| Current Liabilities | $13M | $16.4M | $18.3M | $19.5M | $42.7M | |
| Total Liabilities | $26M | $28.2M | $109.8M | $121.9M | $142.5M | |
| Total Equity | $5.8M | $46.9M | $9.3M | $7.2M | $14.8M | |
| Total Debt | -- | $12.1M | $35.5M | $36.2M | $51.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$34.1M | -$21.5M | -$18.5M | -$7.4M | -$3.1M | |
| Cash From Investing | -$29M | -$3.9M | -$1.6M | -$676K | -$229K | |
| Cash From Financing | $20.7M | $32.3M | $44.6M | -$2.3M | $884K | |
| Free Cash Flow | -$38.3M | -$26.5M | -$20.7M | -$8.4M | -$3.3M | |
MDXH
Sector
Market Cap
$69.8M
$33.7M
Price % of 52-Week High
40.29%
40%
Dividend Yield
0%
0%
Shareholder Yield
-37.33%
-0.91%
1-Year Price Total Return
-43.37%
-46.85%
Beta (5-Year)
-458,274.035
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.4519
200-day SMA
Sell
Level
$2.1828
Bollinger Bands (100)
Sell
Level
1.591 - 2.151
Chaikin Money Flow
Sell
Level
-3.5M
20-day SMA
Sell
Level
$1.5108
Relative Strength Index (RSI14)
Sell
Level
34.6177
ADX Line
Sell
Level
8.5599
Williams %R
Buy
Level
-83.3333
50-day SMA
Sell
Level
$1.6800
MACD (12, 26)
Sell
Level
-0.0720
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Sell
Level
-897.8K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.6675)
Sell
CA Score
(Annual)
Level (-3.1068)
Buy
Beneish M-Score
(Annual)
Level (-2.9617)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (4.7697)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Stock Forecast FAQ
In the current month, MDXH has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MDXH average analyst price target in the past 3 months is $6.0400.
-
Where Will MDxHealth SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that MDxHealth SA share price will rise to $6.0400 per share over the next 12 months.
-
What Do Analysts Say About MDxHealth SA?
Analysts are divided on their view about MDxHealth SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MDxHealth SA is a Sell and believe this share price will drop from its current level to $4.2000.
-
What Is MDxHealth SA's Price Target?
The price target for MDxHealth SA over the next 1-year time period is forecast to be $6.0400 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MDXH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MDxHealth SA is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MDXH?
You can purchase shares of MDxHealth SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MDxHealth SA shares.
-
What Is The MDxHealth SA Share Price Today?
MDxHealth SA was last trading at $1.4200 per share. This represents the most recent stock quote for MDxHealth SA. Yesterday, MDxHealth SA closed at $1.4100 per share.
-
How To Buy MDxHealth SA Stock Online?
In order to purchase MDxHealth SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Archer Aviation a Buy, Sell or Hold?
Vertical takeoff and landing (eVTOL) aircraft sound futuristic but that’s…
Down 50%, Is Dell Technologies a Buy?
Dell (NYSE:DELL)’s share price has been on a roller coaster…
Stock Ideas
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
33
BULZ alert for Apr 10
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 11.43% over the past day.
Sell
48
FNGA alert for Apr 10
MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 10.07% over the past day.
Sell
47
FNGO alert for Apr 10
MicroSectors FANG+ Index 2X Leveraged ETN [FNGO] is down 7.81% over the past day.
